A Study on the Efficacy and Safety of Gabapentin in the Treatment of Patients With Painful Diabetic Neuropathy

PHASE4CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

May 31, 2003

Study Completion Date

August 31, 2004

Conditions
Diabetic Neuropathies
Interventions
DRUG

gabapentin

"Gabapentin oral capsules:~Week 0: Day 1: 300 mg; Day 2: 600 mg (2 doses of 300 mg); Day 3: 900 mg (3 doses of 300 mg), maintained until the end of the week; After this point, the total daily dose was divided in 3 equal doses. Week 1: Day 1: 1200 mg; Day 2 to 7: 1800 mg Week 2: Day 1: 2100 mg; Day 2 to 7: 2400 mg Week 3: Day 1: 2700 mg; Day 2 to 7: 3600 mg Weeks 4 to 11: 3600 mg"

Trial Locations (10)

60120-021

Pfizer Investigational Site, Fortaleza

72119-900

Pfizer Investigational Site, Taguatinga

30150-221

Pfizer Investigational Site, Belo Horizonte

80060-150

Pfizer Investigational Site, Curitiba

52051-380

Pfizer Investigational Site, Recife

20211-340

Pfizer Investigational Site, Rio de Janeiro

Unknown

Pfizer Investigational Site, Porto Alegre

Pfizer Investigational Site

01246-903

Pfizer Investigational Site, São Paulo

04020-041

Pfizer Investigational Site, São Paulo

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00644748 - A Study on the Efficacy and Safety of Gabapentin in the Treatment of Patients With Painful Diabetic Neuropathy | Biotech Hunter | Biotech Hunter